Tailoring HIPEC with Patient-Derived Organoids in Colorectal Peritoneal Metastases: Results from the First Stage of the Prospective Phase II OrganoHIPEC Clinical Trial (Clinicaltrials.gov NCT06057298)
Authors:
- Dario BarattiDBDario Baratti
- Luca VarinelliLVLuca Varinelli
- Marcello GuaglioMGMarcello Guaglio
- Shigeki KusamuraSKShigeki Kusamura
- Tommaso CavalleriTCTommaso Cavalleri
- Davide BattistessaDBDavide Battistessa
- Giovanna SabellaGSGiovanna Sabella
- Gaia CollettiGCGaia Colletti
- Manuela GariboldiMGManuela Gariboldi
- Marcello DeracoMDMarcello Deraco
Open Access
Abstract
Background/Objectives: OrganoHIPEC is a phase-II, two-stage, open-label clinical trial that investigates if cytoreductive surgery (CRS) and patient-tailored HIPEC, based on a preclinical platform using patient-derived organoids, can improve disease control in peritoneal metastases from colorectal cancer (CRC-PM). Methods: Adults with limited CRC-PM and no distant metastases were included. CRC-PM were sampled for organoid development during diagnostic laparoscopy. These organoids were used in an in vitro HIPEC model to test various drugs suitable for intraperitoneal administration. After 3–6 months of systemic chemotherapy, patients without progression underwent CRS/HIPEC with personalized regimens based on organoid drug response. To detect an increase in 12-month peritoneal disease-free survival from 40% to 60%, 24 patients are needed. According to the two-stage design, if n = 14), cisplatin/mitomycin-C (n = 12), and low-dose (120 min) oxaliplatin (n = 4). No patient was sensitive to high-dose oxaliplatin (30 min) and cisplatin/doxorubicin. Ten patients had a potential follow-up >12 months. Peritoneal relapse occurred at 8 months in two patients, and one died of liver metastases at 7 months. Seven patients remained PM-free for >12 months (median 16.4, range 12.6–28.4). Conclusions: A comprehensive precision approach using patient-derived organoids to guide personalized HIPEC is feasible and shows promising early results. High-dose oxaliplatin is poorly active. As 7/10 patients achieved the endpoint of 12-month PM-free survival, Stage-1 was successfully completed. The trial is proceeding to Stage-2.Keywords
Funding Information
- Ministero della Salute (Ricerca Finalizzata RF-2019-12370456)
- Fondazione IRCCS Istituto Nazionale dei Tumori (BRI-2021)
This publication has 48 references indexed in Scilit:
- Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2026
- Efficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon CancerJAMA Surgery, 2023
- Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal MetastasesJAMA Oncology, 2020
- Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapyBritish Journal of Surgery, 2019
- Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer PatientsCell, 2015
- Patterns of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancerJournal of Surgical Oncology, 2014
- Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignanciesJournal of Surgical Oncology, 2009
- Admissible two‐stage designs for phase II cancer clinical trialsStatistics in Medicine, 2004
- Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosisCancer, 2002
- Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis1996